Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem Cell
Mesenchymal stem cell (MSC) has just been approved as the first “off-the-shelf” stem cell pharmaceutical drug with an anticipation of more approvals following completion of numerous rigorous clinical trials. Despite this progress, the rationale for MSC therapeutic efficacy remains tenuous and is inc...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
AboutScience Srl
2013-01-01
|
Series: | Journal of Circulating Biomarkers |
Online Access: | https://doi.org/10.5772/57460 |
id |
doaj-8cbbcd83167c44678d4ac38b699b1766 |
---|---|
record_format |
Article |
spelling |
doaj-8cbbcd83167c44678d4ac38b699b17662020-11-25T03:30:18ZengAboutScience SrlJournal of Circulating Biomarkers1849-45442013-01-01110.5772/57460Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem CellRonne Wee Yeh Yeo0Ruenn Chai Lai1Kok Hian Tan2Sai Kiang Lim3 Institute of Medical Biology, Agency for Science, Technology and Research, Singapore Institute of Medical Biology, Agency for Science, Technology and Research, Singapore Department of Maternal Fetal Medicine, KK Women's and Children's Hospital, Singapore Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, SingaporeMesenchymal stem cell (MSC) has just been approved as the first “off-the-shelf” stem cell pharmaceutical drug with an anticipation of more approvals following completion of numerous rigorous clinical trials. Despite this progress, the rationale for MSC therapeutic efficacy remains tenuous and is increasingly rationalized on a secretion rather than differentiation mechanism. Recent studies identifying exosome as the secreted agent mediating MSC therapeutic efficacy could potentially reduce a cell-based drug to a safer biologic-based alternative. Here we review the development of MSC exosome as a potential first-in-class therapeutic, and the unique challenges in the manufacture and regulatory oversight of this new class of therapeutics.https://doi.org/10.5772/57460 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ronne Wee Yeh Yeo Ruenn Chai Lai Kok Hian Tan Sai Kiang Lim |
spellingShingle |
Ronne Wee Yeh Yeo Ruenn Chai Lai Kok Hian Tan Sai Kiang Lim Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem Cell Journal of Circulating Biomarkers |
author_facet |
Ronne Wee Yeh Yeo Ruenn Chai Lai Kok Hian Tan Sai Kiang Lim |
author_sort |
Ronne Wee Yeh Yeo |
title |
Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem Cell |
title_short |
Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem Cell |
title_full |
Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem Cell |
title_fullStr |
Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem Cell |
title_full_unstemmed |
Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem Cell |
title_sort |
exosome: a novel and safer therapeutic refinement of mesenchymal stem cell |
publisher |
AboutScience Srl |
series |
Journal of Circulating Biomarkers |
issn |
1849-4544 |
publishDate |
2013-01-01 |
description |
Mesenchymal stem cell (MSC) has just been approved as the first “off-the-shelf” stem cell pharmaceutical drug with an anticipation of more approvals following completion of numerous rigorous clinical trials. Despite this progress, the rationale for MSC therapeutic efficacy remains tenuous and is increasingly rationalized on a secretion rather than differentiation mechanism. Recent studies identifying exosome as the secreted agent mediating MSC therapeutic efficacy could potentially reduce a cell-based drug to a safer biologic-based alternative. Here we review the development of MSC exosome as a potential first-in-class therapeutic, and the unique challenges in the manufacture and regulatory oversight of this new class of therapeutics. |
url |
https://doi.org/10.5772/57460 |
work_keys_str_mv |
AT ronneweeyehyeo exosomeanovelandsafertherapeuticrefinementofmesenchymalstemcell AT ruennchailai exosomeanovelandsafertherapeuticrefinementofmesenchymalstemcell AT kokhiantan exosomeanovelandsafertherapeuticrefinementofmesenchymalstemcell AT saikianglim exosomeanovelandsafertherapeuticrefinementofmesenchymalstemcell |
_version_ |
1724576355123724288 |